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In this issue of the Netherlands Heart Journal with a focus
on Atherosclerosis, Cerit and colleagues investigate the im-
pact of statin use on the corrected thrombolysis myocardial
infarction frame count (CTFC) after elective percutaneous
coronary intervention (PCI) [1]. CTFC counts the number
of frames required for contrast material to reach a standard-
ised distal landmark and thereby serves as a surrogate of
coronary blood flow velocity. In this retrospective study, the
authors divide a population of 80 consecutive patients with
stable ischaemic heart disease into two groups based on the
use of statins prior to PCI. The study is observational and
neither randomisation nor propensity score matching has
been applied to mitigate bias. Nevertheless, the baseline
variables of the two groups are well balanced.
In both the statin and control group, CTFC decreased
(coronary flow improved) substantially after PCI. As no
pharmacological agents were given to invoke coronary hy-
peraemia, this observation in itself is interesting and merits
further exploration. Myocardial perfusion is regulated
tightly through myocardial, metabolic and endothelium-
based processes, collectively termed autoregulation [2].
Perfusion is maintained at a stable plateau in the struc-
turally normal heart under resting conditions. The mech-
anism of autoregulation can compensate for the presence
of a stenosis that would otherwise limit coronary flow
[2]. Only in case of very tight lesions (>85% stenosis as
measured by quantitative coronary angiography), does the
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autoregulatory compensation mechanism fall short and is
coronary flow limited under resting conditions (although
well-developed collateral arteries can maintain sufficient
myocardial perfusion). For this reason, true resting coro-
nary flow typically remains unchanged after PCI. Exercise
or vasodilators, such as adenosine, that increase coronary
flow are needed to exhaust the autoregulatory compensa-
tion mechanism and detect an improvement of maximal
flow by PCI. In the studied population, however, CTFC
improved after PCI irrespective of statin prescription. This
could be explained by two factors. Firstly, stenosis diam-
eters were, on average, 80 and 85% in the non-statin and
statin groups, respectively. This suggests that in a propor-
tion of the studied population, stenosis diameter exceeded
85% and autoregulation was exhausted, leading to re-
duced resting flow before PCI [3]. Secondly, there may
have been a pseudo-hyperaemic state after PCI. Contrast
medium itself acts as a vasodilator and interventional car-
diologists that routinely perform fractional flow reserve
measurements may have noticed that an increase in the
pressure gradient can be observed prior to adenosine ad-
ministration, if contrast has just been injected. This is due
to the contrast medium acting as a hyperaemic stimulus
itself. However, the frame counting for CTFC ends early in
injection and well before the dye reaches the microcircula-
tion to develop contrast-induced hyperaemia. Nevertheless,
preceding contrast injections combined with the temporary
balloon occlusion during PCI may have caused downstream
vasodilation. This would render a pseudo-hyperaemic state
when the final fluoroscopic images were acquired, leading
to a ‘falsely’ improved CTFC.
A second finding of interest is that patients on statins
have a significantly higher coronary flow velocity after PCI
compared with control patients who have not been taking
statins. Earlier work with positron emission tomography
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imaging has shown that statin treatment improves myocar-
dial perfusion [4]. However, in this study by Cerit and col-
leagues, the CTFC prior to PCI was statistically equivalent
in the two groups suggesting a different mechanism. The
improved CTFC after PCI is likely attributable to statin
therapy protecting against periprocedural injury to the mi-
crocirculation related to manipulation of the atherosclerotic
plaque. Indeed, the randomised ARMYDA study found that
pre-treatment with atorvastatin for 7 days, resulted in sig-
nificantly reduced rates of PCI-related myocardial injury
in patients with stable ischaemic heart disease [4]. Given
that Cerit and colleagues found serum lipid profiles to be
similar in both groups, the improved CTFC after PCI is
likely attributable to the pleiotropic properties of statins.
The finding that C-reactive protein levels were significantly
decreased in patients on statins as compared with the con-
trol group, suggests a role for the anti-inflammatory proper-
ties of statins in the protection against periprocedural my-
ocardial injury. The authors also discuss improvement of
endothelium-dependent vasodilation mediated by statin as
a possible reason for their findings. This appears less likely,
given that no differences in CTFC between the statin and
control group were observed prior to PCI.
Finally, a note of criticism is in order since CTFC has
several inherent limitations. Firstly, as mentioned above,
CTFC does not measure maximal hyperaemic flow and nu-
merous factors, such as preceding saline or contrast injec-
tions, balloon occlusion and fluctuations in heart rate, may
influence the resting state and CTFC. Secondly, although
CTFC is a quantitative measure, it does partly depend on
contrast injection speed [5]. Alternatives such as positron
emission tomography imaging and invasive Doppler or ther-
modilution-based measurements provide more accurate es-
timations of flow. Thus, the use of CTFC is a clear limi-
tation, even though this paper by Cerit and colleagues ele-
gantly demonstrates potential beneficial pleiotropic effects
of statins before elective PCI. Future studies will need to
verify the current results involving dedicated flow measure-
ments and using a randomised, propensity score matched
or crossover design, before definitive conclusions can be
drawn.
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